Amy L. Leber

Dr. Amy L. Leber


Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 June 2018 in Journal of Clinical Microbiology
Verified
Journal Article
Open access
ALAmy L. Leber
Amy L. Leber
KEKathy Everhart
Kathy Everhart
JDJudy A. Daly
Judy A. Daly
AHAubrey Hopper
Aubrey Hopper
AHAmanda Harrington
Amanda Harrington
BKBart Kensinger
Bart Kensinger
The FilmArray Respiratory Panel 2 (RP2) is a multiplex in vitro diagnostic test for the simultaneous and rapid (∼45-min) detection of 22 pathogens directly from nasopharyngeal swab (NPS) samples. It contains updated (and in some instances redesigned) assays that improve upon the FilmArray Respiratory Panel (RP; version 1.7), with a faster run time. The organisms identified are adenovirus, coronavirus 229E, coronavirus HKU1, coronavirus NL63, coronavirus OC43, human metapneumovirus, human rhinovirus/enterovirus, influenza virus A, influenza virus A H1, influenza virus A H1-2009, influenza virus A H3, influenza virus B, parainfluenza virus 1, parainfluenza virus 2, parainfluenza virus 3, parainfluenza virus 4, respiratory syncytial virus, Bordetella pertussis , Chlamydia pneumoniae , and Mycoplasma pneumoniae . Two new targets are included in the FilmArray RP2: Middle East respiratory syndrome coronavirus and Bordetella parapertussis . This study provides data from a multicenter evaluation of 1,612 prospectively collected NPS samples, with performance compared to that of the FilmArray RP or PCR and sequencing. The overall percent agreement between the FilmArray RP2 and the comparator testing was 99.2%. The RP2 demonstrated a positive percent agreement of 91.7% or greater for detection of all but three analytes: coronavirus OC43, B. parapertussis , and B. pertussis . The FilmArray RP2 also demonstrated a negative percent agreement of ≥93.8% for all analytes. Of note, the adenovirus assay detects all genotypes, with a demonstrated increase in sensitivity. The FilmArray RP2 represents a significant improvement over the FilmArray RP, with a substantially shorter run time that could aid in the diagnosis of respiratory infections in a variety of clinical scenarios.

19 July 2021 in Journal of Clinical Microbiology
Verified
Journal Article
Closed access
HWHuanyu Wang
Huanyu Wang
SJSophonie J Jean
Sophonie J Jean
RERichard Eltringham
Richard Eltringham
JMJohn Madison
John Madison
PSPamela Snyder
Pamela Snyder
ALAmy L. Leber
Amy L. Leber
The emergence of more transmissible and/or more virulent severe acute respiratory syndrome coronavirus type 2 (SARS-CoV-2) variants of concern (VOC) has triggered intensive genomic surveillance, which is costly and difficult to sustain operationally over the long term. To address this problem, we developed a set of four multiplex mutation-specific PCR-based assays with same-day reporting that can detect five VOC and three variants of interest (VOI), as defined in the March 2021 guidelines from the U.S.

23 April 2020 in Journal of Clinical Microbiology
Verified
Journal Article
Open access
PDF file
ALAmy L. Leber
Amy L. Leber
JLJan Gorm Lisby
Jan Gorm Lisby
GHGlen Hansen
Glen Hansen
RRRyan F. Relich
Ryan F. Relich
USUffe Vest Schneider
Uffe Vest Schneider
IHIrene Hannet
Irene Hannet
The QIAstat-Dx Respiratory Panel (QIAstat-Dx RP) is a multiplex in vitro diagnostic test for the qualitative detection of 20 pathogens directly from nasopharyngeal swab (NPS) specimens. The assay is performed using a simple sample-to-answer platform with results available in approximately 69 min. The pathogens identified are adenovirus, coronavirus 229E, coronavirus HKU1, coronavirus NL63, coronavirus OC43, human metapneumovirus A and B, influenza A, influenza A H1, influenza A H3, influenza A H1N1/2009, influenza B, parainfluenza virus 1, parainfluenza virus 2, parainfluenza virus 3, parainfluenza virus 4, rhinovirus/enterovirus, respiratory syncytial virus A and B, Bordetella pertussis , Chlamydophila pneumoniae , and Mycoplasma pneumoniae .

20 June 2023 in Journal of Clinical Microbiology
Verified
Journal Article
Open access
DRDaniel D. Rhoads
Daniel D. Rhoads
SPSpyros Pournaras
Spyros Pournaras
ALAmy L. Leber
Amy L. Leber
JBJoan-Miquel Balada-Llasat
Joan-Miquel Balada-Llasat
AHAmanda Harrington
Amanda Harrington
DLDaisy Y. Lu
Daisy Y. Lu
Diagnostic tools that can rapidly identify and characterize microbes growing in blood cultures are important components of clinical microbiology practice because they help to provide timely information that can be used to optimize patient management. This publication describes the bioMérieux BIOFIRE Blood Culture Identification 2 (BCID2) Panel clinical study that was submitted to the U.S.

21 November 2023 in Journal of Clinical Microbiology
Verified
Journal Article
Open access
Jaime EstebanJaime Esteban
Jaime Esteban
LSLlanos Salar-Vidal
Llanos Salar-Vidal
BSBryan H. Schmitt
Bryan H. Schmitt
AWAmy Waggoner
Amy Waggoner
FLFrédéric Laurent
Frédéric Laurent
BKBart Kensinger
Bart Kensinger
The bioMérieux BIOFIRE Joint Infection (JI) Panel is a multiplex in vitro diagnostic test for the simultaneous and rapid (~1 h) detection of 39 potential pathogens and antimicrobial resistance (AMR) genes directly from synovial fluid (SF) samples. Thirty-one species or groups of microorganisms are included in the kit, as well as several AMR genes. This study, performed to evaluate the BIOFIRE JI Panel for regulatory clearance, provides data from a multicenter evaluation of 1,544 prospectively collected residual SF samples with performance compared to standard-of-care (SOC) culture for organisms or polymerase chain reaction (PCR) and sequencing for AMR genes. The BIOFIRE JI Panel demonstrated a sensitivity of 90.9% or greater for all but six organisms and a positive percent agreement (PPA) of 100% for all AMR genes. The BIOFIRE JI Panel demonstrated a specificity of 98.5% or greater for detection of all organisms and a negative percent agreement (NPA) of 95.7% or greater for all AMR genes. The BIOFIRE JI Panel provides an improvement over SOC culture, with a substantially shorter time to result for both organisms and AMR genes with excellent sensitivity/PPA and specificity/NPA, and is anticipated to provide timely and actionable diagnostic information for joint infections in a variety of clinical scenarios.

17 August 2022 in Journal of Clinical Microbiology
Verified
Journal Article
Open access
ALAmy L. Leber
Amy L. Leber
EPEllena Peterson
Ellena Peterson
JBJennifer Dien Bard
Jennifer Dien Bard
The COVID pandemic has put a spotlight on laboratory medicine, showcasing how vital diagnostic testing is for society and the health care system. It has also brought to light and accelerated the critical shortage of trained and experienced laboratory personnel that has been felt for decades.